Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Home
/
update
/
details

SUNACT Cancer Institute Launches in Thane to Offer Allogeneic CAR-T Cell Therapy

NextEdge Admin

24 Jul 2024

2 min 31 sec

Actor and cancer survivor Mahima Chaudhry recently inaugurated SUNACT Cancer Institute, India's first chain of super-specialized cancer clinics featuring GMP Modular Units. The institute, located at Tieten Medicity Hospital in Thane, is led by renowned oncologists Professor Dr. Vijay Patil and Dr. Ashay Karpe. It offers allogeneic CAR-T Cell Therapy, a cutting-edge treatment that uses donor cells and is effective against solid-state tumors, which make up 99% of cancer cases. This therapy significantly reduces treatment time compared to the autologous version, which is primarily for blood cancers.

SUNACT Cancer Institute aims to advance cancer treatment in India with innovative research and personalized patient care. It provides various therapies, including CAR-T (both allogeneic and autologous), Stem Cell/Bone Marrow Transplants, Gamma Delta T-Cells, Gene Therapy (CRISPR and Gene Editing), Immunotherapy, and advanced chemotherapy.

Dr. Vijay Patil, SUNACT's founder, expressed his commitment to eradicating cancer and highlighted the institute's success in completing India's first allogeneic CAR-T cell therapy at a fraction of the cost compared to Western countries. This breakthrough is expected to save many lives.

Mahima Chaudhry praised the advancements in cancer treatment and expressed gratitude to the medical professionals for their selfless service. She congratulated the entire team for establishing and running the pioneering facility.

SUNACT Cancer Institute plans to open more specialized cancer centers across India, including locations in Mumbai, Delhi/NCR, Bangalore, Pune, Kolkata, and Chennai. By collaborating with international labs, SUNACT aims to provide advanced cancer treatments at affordable costs in underserved markets worldwide, including the Middle East, Africa, and South Asia.